EUVIMEDEUVIMED entdecken
Crossref

Clinical and epidemiological profile of HCV genotype 3 patients in Southern Brazil

Marisa Boff Costa, Larisse Longo, Deivid Santos, Raquel Boff da Costa, Gustavo Hirata Dellavia, Soraia Arruda, Matheus Truccolo Michalczuk, Mário Reis Álvares-da-Silva

Clinical & Biomedical Research · 2020

DOI: 10.22491/2357-9730.100617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Biomedical Research, 2020. Verfasst von Marisa Boff Costa und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and aim. Despite the emergence of new treatments for genotype 3 HCV (G3 HCV), there is still a lack of data about this particular subgroup in Brazil. We aimed to describe clinical and sociodemographic variables and treatment profile of G3 HCV Brazilian patients.

Methods

This was a descriptive, retrospective study, performed in a specialized center for HCV treatment in Brazilian South Region. Medical charts of patients diagnosed with G3 HCV were reviewed to collect clinical, sociodemographic and treatment information. R esults. 564 subjects were enrolled, with mean age of 59.3 years (SD=10.5). Cirrhosis was present in 54.4% of patients. Most common co-existent conditions were systemic arterial hypertension (36.6%) and diabetes mellitus (30.0%). Regarding treatment, 25.2% of patients were treatment-naïve and 74.8% were currently treating (11.6%) or had received a previous treatment (87.0%). The most frequent ongoing treatment was sofosbuvir+daclatasvir(± ribavirin) (87.8%). Of the 388 patients who had at least one previous treatment, 67.0% achieved sustained virologic response in the last treatment. Caucasian/white, non-obese, transplanted patients, those with longer time since diagnosis and with cirrhosis were more likely to receive treatment, according to multivariate analysis. Patients with hepatocellular carcinoma had 64.1% less chance to be on treatment during the study period than those without this condition; patients with chronic kidney disease presents were 2.91-fold more likely to have a treatment interruption than those without.

Conclusion

This study describes a large sample of Brazilian patients with G3 HCV. Treatment patterns were mainly influenced by presence of HCV complications and comorbidities.

Zitieren

APA

Costa, M. B., Longo, L., Santos, D., Costa, R. B. D., Dellavia, G. H., Arruda, S., Michalczuk, M. T., & Álvares-da-Silva, M. R. (2020). Clinical and epidemiological profile of HCV genotype 3 patients in Southern Brazil. Clinical & Biomedical Research. https://doi.org/10.22491/2357-9730.100617

Vancouver

Costa MB, Longo L, Santos D, Costa RBD, Dellavia GH, Arruda S, et al. Clinical and epidemiological profile of HCV genotype 3 patients in Southern Brazil. Clinical & Biomedical Research. 2020. doi:10.22491/2357-9730.100617

BibTeX
@article{Costa2020,
  author = {Costa, Marisa Boff and Longo, Larisse and Santos, Deivid and Costa, Raquel Boff da and Dellavia, Gustavo Hirata and Arruda, Soraia and Michalczuk, Matheus Truccolo and Álvares-da-Silva, Mário Reis},
  title = {Clinical and epidemiological profile of HCV genotype 3 patients in Southern Brazil},
  journal = {Clinical & Biomedical Research},
  year = {2020},
  doi = {10.22491/2357-9730.100617}
}
Kostenlos starten →